Do analysts prefer ITOC or LYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Itonic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher valuation & earnings, ITOC or LYRA?

Itonic has higher earnings, but lower revenue than Lyra Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Itonic $520K 12.96 -$5.10M N/A N/A Lyra Therapeutics $600K 2.37 -$93.43M -$19.15 N/A

Is ITOC or LYRA more profitable?

Itonic has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. Itonic's return on equity of 0.00% beat Lyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Itonic N/A N/A N/A Lyra Therapeutics -5,491.17% -1,010.91% -58.92%

Do analysts recommend GCTK or LYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is GCTK or LYRA more profitable?

GlucoTrack has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. GlucoTrack's return on equity of -581.98% beat Lyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets GlucoTrack N/A -581.98% -220.10% Lyra Therapeutics -5,491.17% -1,010.91% -58.92%

Do analysts prefer ZYXI or LYRA?

Zynex currently has a consensus price target of $4.90, indicating a potential upside of 3,820.00%. Given Zynex's stronger consensus rating and higher possible upside, equities analysts clearly believe Zynex is more favorable than Lyra Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zynex 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings & valuation, ZYXI or LYRA?

Zynex has higher revenue and earnings than Lyra Therapeutics. Zynex is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zynex $108.20M 0.04 $2.99M -$2.43 N/A Lyra Therapeutics $600K 2.37 -$93.43M -$19.15 N/A

Is ZYXI or LYRA more profitable?

Zynex has a net margin of -68.35% compared to Lyra Therapeutics' net margin of -5,491.17%. Zynex's return on equity of -804.30% beat Lyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zynex -68.35% -804.30% -36.67% Lyra Therapeutics -5,491.17% -1,010.91% -58.92%

Do analysts rate BTCY or LYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is BTCY or LYRA more profitable?

Biotricity has a net margin of -80.42% compared to Lyra Therapeutics' net margin of -5,491.17%. Biotricity's return on equity of 0.00% beat Lyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Biotricity -80.42% N/A -188.47% Lyra Therapeutics -5,491.17% -1,010.91% -58.92%

Do analysts recommend AEMD or LYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aethlon Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Lyra Therapeutics (LYRA) Competitors

$0.80 +0.10 (+14.29%)

As of 06/9/2026 03:04 PM Eastern

Compare

LYRA vs. ITOC, GCTK, ZYXI, BTCY, and AEMD

Should you buy Lyra Therapeutics stock or one of its competitors? MarketBeat compares Lyra Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lyra Therapeutics include Itonic (ITOC), GlucoTrack (GCTK), Zynex (ZYXI), Biotricity (BTCY), and Aethlon Medical (AEMD). These companies are all part of the "medical equipment" industry.

How does Lyra Therapeutics compare to Itonic?

Itonic (NASDAQ:ITOC) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Itonic has a beta of 2.78, indicating that its share price is 178% more volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

In the previous week, Itonic had 7 more articles in the media than Lyra Therapeutics. MarketBeat recorded 7 mentions for Itonic and 0 mentions for Lyra Therapeutics. Itonic's average media sentiment score of 0.41 beat Lyra Therapeutics' score of 0.00 indicating that Itonic is being referred to more favorably in the media.

Company	Overall Sentiment
Itonic	Neutral
Lyra Therapeutics	Neutral

95.6% of Lyra Therapeutics shares are owned by institutional investors. 3.3% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Itonic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Itonic has higher earnings, but lower revenue than Lyra Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Itonic	$520K	12.96	-$5.10M	N/A	N/A
Lyra Therapeutics	$600K	2.37	-$93.43M	-$19.15	N/A

Itonic has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. Itonic's return on equity of 0.00% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Itonic	N/A	N/A	N/A
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

Summary

Itonic beats Lyra Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Lyra Therapeutics compare to GlucoTrack?

GlucoTrack (NASDAQ:GCTK) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

GlucoTrack has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

GlucoTrack has higher earnings, but lower revenue than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A
Lyra Therapeutics	$600K	2.37	-$93.43M	-$19.15	N/A

GlucoTrack has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. GlucoTrack's return on equity of -581.98% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-581.98%	-220.10%
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, GlucoTrack had 2 more articles in the media than Lyra Therapeutics. MarketBeat recorded 2 mentions for GlucoTrack and 0 mentions for Lyra Therapeutics. GlucoTrack's average media sentiment score of 0.43 beat Lyra Therapeutics' score of 0.00 indicating that GlucoTrack is being referred to more favorably in the media.

Company	Overall Sentiment
GlucoTrack	Neutral
Lyra Therapeutics	Neutral

10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 2.2% of GlucoTrack shares are held by insiders. Comparatively, 3.3% of Lyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

GlucoTrack beats Lyra Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Lyra Therapeutics compare to Zynex?

Zynex (NASDAQ:ZYXI) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

In the previous week, Zynex had 1 more articles in the media than Lyra Therapeutics. MarketBeat recorded 1 mentions for Zynex and 0 mentions for Lyra Therapeutics. Zynex's average media sentiment score of 0.91 beat Lyra Therapeutics' score of 0.00 indicating that Zynex is being referred to more favorably in the media.

Company	Overall Sentiment
Zynex	Positive
Lyra Therapeutics	Neutral

29.7% of Zynex shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 49.3% of Zynex shares are owned by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Zynex has a net margin of -68.35% compared to Lyra Therapeutics' net margin of -5,491.17%. Zynex's return on equity of -804.30% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zynex	-68.35%	-804.30%	-36.67%
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

Zynex currently has a consensus price target of $4.90, indicating a potential upside of 3,820.00%. Given Zynex's stronger consensus rating and higher possible upside, equities analysts clearly believe Zynex is more favorable than Lyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zynex	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Zynex has higher revenue and earnings than Lyra Therapeutics. Zynex is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zynex	$108.20M	0.04	$2.99M	-$2.43	N/A
Lyra Therapeutics	$600K	2.37	-$93.43M	-$19.15	N/A

Zynex has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

Summary

Zynex beats Lyra Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Lyra Therapeutics compare to Biotricity?

Biotricity (NASDAQ:BTCY) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 10.1% of Biotricity shares are owned by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Biotricity has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Biotricity's average media sentiment score of 0.00 equaled Lyra Therapeutics'average media sentiment score.

Company	Overall Sentiment
Biotricity	Neutral
Lyra Therapeutics	Neutral

Biotricity has higher revenue and earnings than Lyra Therapeutics. Biotricity is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06M	0.28	-$14.09M	-$0.16	N/A
Lyra Therapeutics	$600K	2.37	-$93.43M	-$19.15	N/A

Biotricity has a net margin of -80.42% compared to Lyra Therapeutics' net margin of -5,491.17%. Biotricity's return on equity of 0.00% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

Summary

Biotricity beats Lyra Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Lyra Therapeutics compare to Aethlon Medical?

Aethlon Medical (NASDAQ:AEMD) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Aethlon Medical has higher earnings, but lower revenue than Lyra Therapeutics. Aethlon Medical is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aethlon Medical	N/A	N/A	-$13.39M	-$14.69	N/A
Lyra Therapeutics	$600K	2.37	-$93.43M	-$19.15	N/A

In the previous week, Aethlon Medical had 3 more articles in the media than Lyra Therapeutics. MarketBeat recorded 3 mentions for Aethlon Medical and 0 mentions for Lyra Therapeutics. Aethlon Medical's average media sentiment score of 0.22 beat Lyra Therapeutics' score of 0.00 indicating that Aethlon Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Aethlon Medical	Neutral
Lyra Therapeutics	Neutral

2.0% of Aethlon Medical shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 0.7% of Aethlon Medical shares are owned by insiders. Comparatively, 3.3% of Lyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aethlon Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Aethlon Medical has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Aethlon Medical has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. Aethlon Medical's return on equity of -219.39% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aethlon Medical	N/A	-219.39%	-164.33%
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

Summary

Aethlon Medical beats Lyra Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Lyra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LYRA vs. The Competition

Export

Metric	Lyra Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.42M	$2.96B	$6.64B	$12.06B
Dividend Yield	N/A	1.71%	2.67%	5.55%
P/E Ratio	-0.03	17.78	24.50	23.76
Price / Sales	2.37	287.11	503.68	105.22
Price / Cash	N/A	55.74	42.36	56.09
Price / Book	0.09	3.88	10.36	6.72
Net Income	-$93.43M	$75.85M	$3.56B	$337.35M
7 Day Performance	21.21%	-1.11%	-1.01%	-1.21%
1 Month Performance	9.59%	-5.33%	1.21%	1.41%
1 Year Performance	-94.84%	13.23%	20.40%	23.64%

Lyra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LYRA Lyra Therapeutics	0.2383 of 5 stars	$0.80 +14.3%	N/A	-95.7%	$1.42M	$600K	N/A	50	Gap Down
ITOC Itonic	0.8902 of 5 stars	$0.29 -3.7%	N/A	N/A	$5.12M	$523.03K	N/A	N/A	Positive News Short Interest Decrease Gap Up
GCTK GlucoTrack	0.3434 of 5 stars	$0.65 -1.2%	N/A	-94.5%	$4.13M	N/A	N/A	5	Short Interest Increase
ZYXI Zynex	3.0924 of 5 stars	$0.13 flat	$4.90 +3,820.0%	N/A	$3.80M	$108.20M	N/A	770	News Coverage
BTCY Biotricity	N/A	$0.11 -12.8%	N/A	-76.2%	$3.75M	$12.06M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LYRA) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lyra Therapeutics (LYRA) Competitors

LYRA vs. ITOC, GCTK, ZYXI, BTCY, and AEMD

How does Lyra Therapeutics compare to Itonic?

Summary

How does Lyra Therapeutics compare to GlucoTrack?

Summary

How does Lyra Therapeutics compare to Zynex?

Summary

How does Lyra Therapeutics compare to Biotricity?

Summary

How does Lyra Therapeutics compare to Aethlon Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYRA vs. The Competition

Lyra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lyra Therapeutics (LYRA) Competitors

LYRA vs. ITOC, GCTK, ZYXI, BTCY, and AEMD

How does Lyra Therapeutics compare to Itonic?

Which has more risk & volatility, ITOC or LYRA?

Does the media refer more to ITOC or LYRA?

Do institutionals and insiders have more ownership in ITOC or LYRA?

Do analysts prefer ITOC or LYRA?

Which has higher valuation & earnings, ITOC or LYRA?

Is ITOC or LYRA more profitable?

Summary

How does Lyra Therapeutics compare to GlucoTrack?

Which has more risk and volatility, GCTK or LYRA?

Which has stronger earnings & valuation, GCTK or LYRA?

Is GCTK or LYRA more profitable?

Do analysts recommend GCTK or LYRA?

Does the media refer more to GCTK or LYRA?

Do institutionals and insiders believe in GCTK or LYRA?

Summary

How does Lyra Therapeutics compare to Zynex?

Does the media refer more to ZYXI or LYRA?

Do insiders & institutionals have more ownership in ZYXI or LYRA?

Is ZYXI or LYRA more profitable?

Do analysts prefer ZYXI or LYRA?

Which has better earnings & valuation, ZYXI or LYRA?

Which has more volatility & risk, ZYXI or LYRA?

Summary

How does Lyra Therapeutics compare to Biotricity?

Do insiders & institutionals have more ownership in BTCY or LYRA?

Which has more risk and volatility, BTCY or LYRA?

Do analysts rate BTCY or LYRA?

Does the media favor BTCY or LYRA?

Which has preferable earnings & valuation, BTCY or LYRA?

Is BTCY or LYRA more profitable?

Summary

How does Lyra Therapeutics compare to Aethlon Medical?

Which has stronger valuation & earnings, AEMD or LYRA?

Does the media refer more to AEMD or LYRA?

Do institutionals and insiders have more ownership in AEMD or LYRA?

Do analysts recommend AEMD or LYRA?

Which has more volatility and risk, AEMD or LYRA?

Is AEMD or LYRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYRA vs. The Competition

Lyra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools